Biotech Equity Investments at a Premium to Market, Part II
Executive Summary
In Vivo breaks out equity investments at a premium to market in biotech deals from 1993 to 1995, comparing those in which the program licensed was in the R&D stage to those in which there was a product in Phase I or later.